Gilead Sciences Appoints Peter Wickersham to Vice-President and General Manager in the UK and Ireland
May 7, 2024 – Drug Discovery, Pharmaceutical – Gilead Sciences, appointments, hepatitis C, liver disease
7 May 2024 — London, UK — Gilead Sciences announced today the appointment of Peter Wickersham as vice-president and general manager for the UK and Ireland. In his new role, Wickersham will be responsible for leading Gilead’s commercial organisation in the affiliate with a focus on driving growth and advancing patient care across all of Gilead’s portfolio of innovative products.
With more than 25 years of experience in the pharmaceutical industry, Wickersham brings a wealth of commercial expertise and strategic acumen to his new role. More recently, he led Gilead’s Liver Disease and COVID-19 Business Unit in the US, and prior to that, he was vice-president of US Managed Markets. Before joining Gilead, he held senior positions at Express Scripts, Prime Therapeutics and Merck & Co (MSD outside the US).
“I am thrilled to join Gilead’s UK and Ireland organisation at such a pivotal time. We stand on the brink of eliminating Hepatitis C, we continue to pioneer advancements in HIV care and prevention and we are reshaping the landscape of cancer treatment. The dedication and determination of our team are unmatched, and I am eager to lead them into the next phase of our journey,” said Wickersham as he assumes the leadership of the UK and Ireland organisation.
Commenting on the appointment, Josephine Comiskey, senior vice-president, Gilead Sciences, Australia-Canada-Europe said, ‘Under Pete’s leadership, we are looking forward to strengthening our partnerships across the UK and Ireland, addressing the unique challenges faced by the country’s healthcare landscape. As we work towards our ambitious goals of eliminating, preventing and managing some of the world’s most serious diseases, Pete’s expertise will be instrumental in navigating the complexities of the UK’s and Ireland’s healthcare system and addressing the specific needs of patients and healthcare providers alike.’
Wickersham holds master’s degrees in applied statistics, nuclear science and engineering, as well as management. He is relocating from California with his wife to embark on this new chapter in the UK, while his two children will continue to pursue their university studies in America. He succeeds Véronique Walsh, who now assumes the role of president of Gilead Sciences France.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California, US. Visit: www.gilead.com.
